LAVA-051 for the treatment of CLL was granted an orphan drug designation by the FDA. Results of a phase 1 study of the agent are expected in the first half of 2022.
Sara Karlovitch
Sara Karlovitch is an associate editor with Targeted Oncology. She received a duel degree in Journalism and Government and Politics from the University of Maryland.
Articles by Sara Karlovitch
The combination had a 24-month OS rate of 80%.
Obinutuzumab is associated with greater toxicity compare to rituximab in follicular lymphoma.
In an interview with Targeted Oncology for Metastatic Breast Cancer Awareness Day, O’Regan discussed how the metastatic breast cancer landscape has changed and suggested potential regimens that could further that change.
The CAR T-cell therapy may provide another therapy option for patients with large B-cell lymphoma.
Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses the need for new drugs after patients with myelofibrosis are treated with JAK inhibitors.
A new database organizes information on driver mutations for researchers.
In an interview with Targeted Oncology, Jason Westin, MD, discussed the future of DLBCL treatment in both the frontline and later-line settings, along with current unmet clinical needs.
Following a safety evaluation, the FDA has lifter its clinical hold of studies of rusfertide.
Climate change is already having major impacts on the cancer patient population.
The designation is based on a phase 1/2 study of the agent in patients 3-19 years of age.
The study is currently recruiting in Chicago, Illinois.
In an interview with Targeted Oncology, Richard Anderson, PhD discussed how fertility is impacted by many lymphoma treatments, and what can be done to help preserve fertility in patients prior to treatment.
The 140 mg dosage was associated with a higher rate of adverse events and dose reductions.
Further research is warranted after a phase 1 study found the agent has a good safety profile with clinical efficacy.
The breakthrough therapy designation marks the agents seventh regulatory designation.
In an interview with Targeted Oncology™: Jeffrey Miller, MD, discussed the use of NK cell destruction to boost IL-15 efficacy in refractory tumors.
In an interview with Targeted Oncology, Marshall Posner, MD, discusses the use of the HB-201 and HB-202 vaccines in patients with human papillomavirus 16- positive cancers.
In an interview with Targeted Oncology, Patrick Connor Johnson, MD, discussed the top considerations taken into account by physicians when choosing a third-line therapy for diffuse large B-cell lymphoma.
Axi-cel developer seeks to expand Axi-Cel for large B-cell lymphoma application to include the second-line setting.
NUC-1031, a drug for the first-line treatment of patients with advanced biliary tract cancer, has been granted fast track designation by the FDA.
The last patient has been enrolled in the phase 2 MOUNTAINEER trial, evaluating tucatinib both as a monotherapy and in combination with trastuzumab for the treatment of HER2-positive metastatic colorectal cancer following previous first- and second-line standard of care therapies.
The FDA has approved cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer harboring a BRAF V600E mutation, after prior therapy.
Theodore W. Laetsch, MD, an attending physician with the Cancer Center at Children’s hospital of Philadelphia discusses if there is an increased risk of fractures with larotrectinib in patients with TRK fusion positive thyroid cancer.
Principle study investigator Yuliya Mikheeva, MD, PhD, of Saint-Petersburg State University, discussed the combination of dabrafenib and trametinib for the treatment of anaplastic thyroid cancer in an interview with Targeted Oncology.
The Cancer and Aging Research Group calculator is a quick and helpful tool to help assess chemotherapy toxicity in geriatric patients, according to research highlighted in a press release by the Yale School of Medicine.
Genomic and biomarker testing is increasing at OneOncology community cancer centers across a number of tumor types.
Pembrolizumab led to improvement in overall survival compared to placebo in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
In an interview with Targeted Oncology™, Ingrid Glimelius, MD, PhD, discusses the importance of long-term surveillance in lymphoma survivors.
The FDA authorized the marketing of Paige Prostate, the first ratification-intelligence-based software designed to identify areas with high likelihood of cancer on images from a prostate biopsy.